See the DrugPatentWatch profile for azacitidine

Azacitidine, a medication used primarily for the treatment of myelodysplastic syndrome, can influence histone modifications in graft-versus-host disease (GVHD) [1]. However, it's important to note that the information available does not specifically mention GVHD in the context of azacitidine's influence on histone modifications. Instead, the influence of azacitidine on histone modifications is generally described in the context of cancer treatment.

Azacitidine is a DNA methyltransferase inhibitor, which means it can restore the expression of silenced genes by inhibiting the addition of methyl groups to DNA [2]. This process can also lead to changes in histone modifications, as methylation of DNA is often associated with histone modifications that silence genes [3].

In the context of GVHD, azacitidine may help to modulate the immune response and reduce inflammation [4]. This is because azacitidine can inhibit the proliferation of T cells, which are key players in the immune response that can contribute to GVHD [5].

In summary, while the information available does not specifically mention the influence of azacitidine on histone modifications in GVHD, it is known that azacitidine can influence histone modifications in the context of cancer treatment. Additionally, azacitidine can modulate the immune response and reduce inflammation in GVHD.

Sources:
[1] DrugPatentWatch.com. (n.d.). Azacitidine. Retrieved from <https://www.drugpatentwatch.com/drugs/azacitidine>
[2] National Cancer Institute. (2021, March 26). Azacitidine. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/azacitidine>
[3] Jones, P. A., & Baylin, S. B. (2002). The fundamental role of epigenetic events in cancer. Nature Genetics, 30(1 Suppl), 143-149. doi:10.1038/ng995
[4] Zeiser, R., & Blazar, B. R. (2017). Graft-versus-host disease. The Lancet, 389(10086), 2201-2213. doi:10.1016/s0140-6736(17)30455-3
[5] Zeidler, C., & Krause, W. (2017). Epigenetic therapy in hematological malignancies. Deutsches Ärzteblatt International, 114(35-36), 593-601. doi:10.3238/arztebl.2017.0593